Alkermes plc (ALKS) AI Stock Analysis

Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, that researches, develops, and commercializes pharmaceutical products addressing unmet medical needs. Its commercial portfolio and pipeline span schizophrenia, bipolar I disorder, alcohol and opioid dependence, and multiple sclerosis. Key commercial products include ARISTADA, a long-acting treatment for schizophrenia, and VIVITROL, which helps prevent alcohol and opioid dependence. The company also developed formulations such as INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA for schizophrenia management through collaborations with partners like Janssen Pharmaceutica. Additional pipeline candidates include LYBALVI for schizophrenia and bipolar I disorder, and nemvaleukin alfa for oncology.

Alkermes posted a 5-year revenue CAGR of 7.3% from FY2020 through FY2025. Annual revenue grew 49.6% in FY2023 to $1.66B before contracting 6.4% in FY2024 to $1.56B and falling 5.2% in FY2025 to $1.48B. Gross margin expanded to 86.7% in FY2025 from 84.2% in FY2024, while net margin fell to 16.4% with net income of $241.7M. For the latest quarter ending June 30, 2026, quarterly revenue grew 27.0% year-over-year, while quarterly earnings declined 99.4%. R&D expense increased to $324.0M in FY2025 compared to $245.3M in FY2024.

As of June 30, 2026, Alkermes held $656.6M in cash and short-term investments against total debt of $1.57B, resulting in net debt of $916.0M. The company maintains a current ratio of 2.30 and a debt-to-equity ratio of 0.87 on shareholders' equity of $1.81B. During FY2025, capital expenditures totaled $40.4M and the company used $31.0M for share buybacks. Five-year share count change was 3.0%.

Alkermes trades at a trailing P/E of 108.5x and a forward P/E of 133.3x, both well above the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales multiple of 4.1x matches the peer median of 4.1x, while its EV/EBITDA of 36.6x exceeds the peer median of 12.0x. Over the past year, the stock returned 33.8%, outperforming the S&P 500 (SPY) return of 16.8%, but its 5-year return of 30.2% trails the index return of 83.0%.

Wall Street coverage includes 11 Strong Buy, 3 Buy, 4 Hold, and 1 Sell ratings. The mean price target is $56.21, representing a potential upside of 36.4% over the last close of $41.22. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $1.27, representing a decline of 39.2%, on revenue of $1.82B. Alkermes beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for October 27, 2026.

This page is an AI-written research summary of Alkermes plc (ALKS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALKS income statement, ALKS balance sheet, ALKS key metrics, ALKS analyst forecast, ALKS chart. See the ALKS stock overview for the latest quote and news.